WATCH – Is Your NPD Pipeline Ready for GLP-1?

For NPD teams, the ripple effect is impossible to ignore. As consumers on GLP-1 medications eat less and change what they reach for, entire categories are being disrupted. Two in three users report cutting back on both snacks and pizza, signalling a shift in everyday eating that’s redefining portion sizes, formats and the role of indulgence

But this isn’t only about weight loss. GLP-1 drugs are also showing profound benefits for cardiovascular, kidney, and liver diseases, alongside promising effects in addiction therapy and neurodegenerative conditions. As research expands and new applications emerge, wider usage is inevitable, meaning this shift in consumer behaviour will only accelerate.

At the same time, key patents are set to expire in 2026, opening the door to more affordable and accessible GLP-1 medications. This will drive seismic changes in how consumers shop, snack, and satisfy hunger.

Watch our panel of industry experts as we unpack what’s really happening and how NPD teams can use this as an opportunity.

In this panel, we explore:

Which categories are gaining and losing share

+ How appetite suppression is reshaping NPD briefs and priorities

+ Case studies of manufacturers adapting their product pipelines

+ Actionable frameworks to meet changing needs

Read more about the GLP-1 impact on the food industry here:

+ How GLP-1 is changing food categories

+ Is GLP-1 changing consumer choices for good?